Loading clinical trials...

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

A Randomized, Double-Blind, Placebo- Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder

NCT04693351•Biohaven Pharmaceuticals, Inc.

Summary

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Primary diagnosis of obsessive-compulsive disorder (OCD) as per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition as confirmed by the MINI at screening; the duration of the subjects illness must be ≥ 1year
•2. An inadequate response to current Standard of Care medication defined as selective serotonin reuptake inhibitor (excluding fluvoxamine) or clomipramine treatment at an adequate and stable dose for at least 8 weeks prior to screening and at least 12 weeks at baseline (adequate dose defined by USPI labeling); an inadequate response too current standard of car base on the YBOCS score.
•3. Determined by the investigator to be medically stable at baseline/ randomization as assessed by medical history, physical examination, laboratory test results, and electrocardiogram testing. Subjects must be physically able and expected to complete the trail as designed.

Exclusion Criteria

•1. Subjects with a history of more than two (2) previous failed or inadequate treatment classes given for an adequate duration at an adequate dose as defined by the MGH-TRQ-OCD.
•2. Current or prior history of: bipolar I or II disorder, schizophrenia or other psychotic disorders, schizoaffective disorder, autism or autism spectrum disorders, borderline personality disorder, antisocial personality disorder, Tourette's disorder, body dysmorphic disorder, hoarding disorder, or psychosurgery, Deep Brain Stimulation (DBS) or Electroconvulsive Therapy (ECT); or general medical condition that may confound safety and/or efficacy results.
•3. Previous treatment in a study with troriluzole

Locations (89)

Alea Research

Phoenix, Arizona, United States

ProScience Research Group

Culver City, California, United States

Kaizen Brain Center

La Jolla, California, United States

Om Research LLC

Lancaster, California, United States

CalNeuro Research Group

Los Angeles, California, United States

Lumos Clinical Research Center, LLC

San Jose, California, United States

Velocity Clinical Research

Santa Ana, California, United States

California Neuroscience Research Medical Group, Inc.

Sherman Oaks, California, United States

Pacific Clinical Research Medical Group

Upland, California, United States

Mountain View Clinical Research

Denver, Colorado, United States

Key Dates

Start Date

January 29, 2021

Primary Completion Date

April 29, 2025

Completion Date

April 29, 2025

Last Updated

August 19, 2025

Enrollment

589

ACTUAL participants

Conditions

Obsessive-Compulsive Disorder

Interventions

Troriluzole

DRUG

Placebo

DRUG

Acceptance and Commitment Therapy for Religious OCD

NCT06647589

Obsessive-Compulsive Disorder (OCD)

View study

RECRUITING

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918

Treatment Resistant DepressionMajor Depressive Episode+5 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Inclusion Criteria

Exclusion Criteria

Acceptance and Commitment Therapy for Religious OCD

University of Iowa Interventional Psychiatry Service Patient Registry

SEEG-Guided DBS for OCD

Virtual Reality Exposure Therapy for Obsessive-Compulsive Disorder: A Randomized Controlled Trial in Inpatients

Brief Culturally Adapted CBT for OCD

Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD